Transgene shares dip as therapeutic cancer vaccine disappoints in Phase 2 trial
Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its shares down around 14% Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.